Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance

NACompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

May 31, 2018

Study Completion Date

May 31, 2018

Conditions
HIV Related Insulin ResistanceProtease Inhibitor Related Insulin ResistanceEndoplasmic Reticulum Stress
Interventions
DRUG

Tauroursodeoxycholic acid

The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.

OTHER

Placebo tablet

The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Washington University School of Medicine

OTHER

NCT01877551 - Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance | Biotech Hunter | Biotech Hunter